Holen Sie sich die Stockscreener-App
6.47
0.47%
0.03
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Is Kura Oncology Inc. a good long term investmentFree Real-Time Stock Data - Autocar Professional
Will Kura Oncology Inc. stock benefit from interest rate changesFree Stock Chart Pattern Guide - jammulinksnews.com
Can Kura Oncology Inc. stock recover from recent declineFree Predictions - jammulinksnews.com
What analysts say about Kura Oncology Inc. stockExplosive returns - Autocar Professional
What drives Kura Oncology Inc. stock priceAccelerated wealth building - jammulinksnews.com
Kura Oncology Inc. Stock Analysis and ForecastExplosive earnings growth - jammulinksnews.com
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Why Kura Oncology Inc. stock attracts strong analyst attentionFree AI-Driven Trading Strategies - Newser
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - Yahoo Finance
How Kura Oncology Inc. stock performs during market volatilityFree Access to Group - Newser
What makes Kura Oncology Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt? - simplywall.st
Wealth Enhancement Advisory Services LLC Takes $139,000 Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology shares rise 3.34% after-hours following inducement grants to new employees. - AInvest
Kura Oncology's Ziftomenib: A Near-Term FDA Catalyst and a Paradigm Shift for AML Patients - AInvest
Kura Oncology Partners with Kyowa Kirin for Ziftomenib - TipRanks
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.com
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US By Investing.com - Investing.com South Africa
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 3000E Value Index - MarketScreener
Kura Oncology (NASDAQ:KURA) Given Overweight Rating at Cantor Fitzgerald - Defense World
KURA: Cantor Fitzgerald Reiterates Overweight Rating | KURA Stoc - GuruFocus
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Rhumbline Advisers - Defense World
KURA: Wedbush Reiterates 'Outperform' Rating with $36 Price Target | KURA Stock News - GuruFocus
Transcript : Kura Oncology, Inc.Special Call - MarketScreener
Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks
Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Australia
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):